Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Myelofibrosis · Acute Myeloid Leukemia

Karyopharm Therapeutics

Karyopharm Therapeutics Inc

Karyopharm Therapeutics clinical programs — 82 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
85 Wells Avenue, Newton, MA 02459, US HQ
313 Employees
NMPA registrant Type
Company details
Status
Public
HQ
85 Wells Avenue, Newton, MA 02459, US
Employees
313
Programs
82
Drugs
53
Patents
38
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Karyopharm Therapeutics projects

82 ClinicalTrials.gov programs sponsored by Karyopharm Therapeutics.

Karyopharm Therapeutics has 82 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

82 programs

Clinical programs

Page 2 of 2

  1. Selinexor

    Karyopharm Therapeutics Inc

    Thymoma

    phase 2 small molecule active

    1 trial

  2. Selinexor (KPT-330)

    Karyopharm Therapeutics Inc

    Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial

  3. Selinexor 100 mg

    Karyopharm Therapeutics Inc

    Non-Small Cell Lung Carcinoma (NSCLC)

    phase 2 small molecule completed

    1 trial

  4. Selinexor 20 MG Oral Tablet

    Karyopharm Therapeutics Inc

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  5. Selinexor 60 MG

    Karyopharm Therapeutics Inc

    Multiple Myeloma

    phase 2 small molecule on hold

    1 trial

  6. Selinexor 60 mg

    Karyopharm Therapeutics Inc

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  7. XPORT-MF-044

    Karyopharm Therapeutics Inc

    moderate thrombocytopenia, JAK inhibitor-naïve myelofibrosis

    phase 2 small molecule active

    1 trial

  8. XPORT-MM-028

    Karyopharm Therapeutics Inc

    Penta-refractory multiple myeloma and triple-class refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  9. selinexor

    Karyopharm Therapeutics Inc

    Richter's Transformation

    phase 2 small molecule terminated

    1 trial

  10. selinexor (KPT-330)

    Karyopharm Therapeutics Inc

    Myelodysplastic Syndromes

    phase 2 small molecule completed

    1 trial

  11. Eltanexor

    Karyopharm Therapeutics Inc

    Relapsed Myelodysplastic Syndrome

    phase 1 small molecule active

    1 trial

  12. KCP-330

    Karyopharm Therapeutics Inc

    Sarcoma

    phase 1 small molecule completed

    1 trial

  13. KPT-330

    Karyopharm Therapeutics Inc

    Hematological Malignancies

    phase 1 small molecule completed

    1 trial

  14. KPT-330

    Karyopharm Therapeutics Inc

    Diffuse Large B-Cell Lymphoma

    phase 1 small molecule completed

    1 trial

  15. KPT-330

    Karyopharm Therapeutics Inc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  16. KPT-330

    Karyopharm Therapeutics Inc

    Relapsed Acute Lymphoblastic Leukemia (ALL)

    phase 1 small molecule active

    1 trial

  17. KPT-9274

    Karyopharm Therapeutics Inc

    Acute Myeloid Leukemia

    phase 1 small molecule completed

    1 trial

  18. KPT-9274

    Karyopharm Therapeutics Inc

    Solid Tumors

    phase 1 small molecule terminated

    1 trial

  19. Selinexor

    Karyopharm Therapeutics Inc

    Colorectal Neoplasm

    phase 1 small molecule terminated

    1 trial

  20. Selinexor

    Karyopharm Therapeutics Inc

    Solid Tumor

    phase 1 small molecule completed

    1 trial

  21. Selinexor

    Karyopharm Therapeutics Inc

    Liposarcoma

    phase 1 small molecule terminated

    1 trial

  22. Selinexor

    Karyopharm Therapeutics Inc

    Prolymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  23. Selinexor

    Karyopharm Therapeutics Inc

    Refractory Multiple Myeloma

    phase 1 small molecule active

    1 trial

  24. Selinexor

    Karyopharm Therapeutics Inc

    Amyloid

    phase 1 small molecule terminated

    1 trial

  25. Selinexor

    Karyopharm Therapeutics Inc

    Soft Tissue Sarcoma

    phase 1 small molecule completed

    1 trial

  26. Selinexor Pill

    Karyopharm Therapeutics Inc

    Hepatocellular Carcinoma

    phase 1 small molecule terminated

    1 trial

  27. Venetoclax

    Karyopharm Therapeutics Inc

    Acute Leukemia of Ambiguous Lineage in Relapse

    phase 1 small molecule active

    1 trial

  28. Venetoclax

    Karyopharm Therapeutics Inc

    Diffuse Large B-cell Lymphoma

    phase 1 small molecule completed

    1 trial

  29. Verdinexor

    Karyopharm Therapeutics Inc

    Healthy

    phase 1 small molecule terminated

    1 trial

  30. decitabine

    Karyopharm Therapeutics Inc

    Acute Myeloid Leukemia

    phase 1 small molecule completed

    1 trial

  31. mitoxantrone hydrochloride

    Karyopharm Therapeutics Inc

    Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

    phase 1 small molecule completed

    1 trial

  32. selinexor

    Karyopharm Therapeutics Inc

    B-cell Lymphoma

    phase 1 small molecule completed

    1 trial

  33. selinexor

    Karyopharm Therapeutics Inc

    Recurrent Melanoma

    phase 1 small molecule completed

    1 trial

  34. standard dose capecitabine

    Karyopharm Therapeutics Inc

    Rectal Neoplasms

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Karyopharm Therapeutics have?

82 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.